Gomiliximab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD23 |
| Identifiers | |
| CAS Number | 357613-86-6  |
| ATC code | none |
| ChemSpider | none |
| UNII | 8Z13S29R5A  |
| KEGG | D06463 |
| (what is this?) (verify) |
|
Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23).[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
This drug was developed by IDEC Pharmaceuticals Corporation.
References[edit]
- ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council - Gomiliximab, American Medical Association.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
